NEW YORK, May 14 – Bioinformatics company Informax said Monday it signed a deal in the first quarter to license its Genomax software to Cellular Genomics.
An Informax spokeswoman said the deal was recorded in the company’s first quarter earnings although the official announcement was held up due to internal delays.
“These products will form a key element of CGI's bioinformatics infrastructure, allowing us to rapidly meet our needs of high throughput sequence analysis for our protein-protein interaction screens, as well as gene expression analysis for our target validation work,” Andy Whitney, Cellular Genomics’ director of bioinformatics, said in a statement.
Terms of the deal were not disclosed.
Genomax is an enterprise system that supports high-throughput research. Genomax can handle genomic and proteomic data, including sequence information, gene expression data, and protein structure.
To date, Informax of Bethesda, Md., has licensed Genomax to over 30 pharmaceutical, biotechnology, and academic customers.
Cellular Genomics of Branford, Conn., identifies and validates novel drug targets and plans to develop its own pharmaceutical products.